{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:28:23Z","timestamp":1763706503078,"version":"3.37.3"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Hygiene and Health Development Scientific Research Fostering Plan of Haidian District Beijing","award":["HP2021-31-50302"],"award-info":[{"award-number":["HP2021-31-50302"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematopathol"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Overexpression of PD-L1 can be a predictive marker for anti-PD-1 therapeutic efficacy in classic Hodgkin lymphoma (CHL); however, harmonization of different IHC assays remains to be accomplished, and interpretations of PD-L1 immunostaining results remain controversial in CHL. In this study, we sought to optimize the PD-L1 immunohistochemistry (IHC) assay in CHL. All tests were performed on a tumour tissue microarray established from 54 CHL cases. Three IHC antibodies (405.9A11, SP142, 22C3) for detecting PD-L1 expression were compared semi quantitatively with the RNAscope assay (No. 310035, ACD), and the difference in the expression in background immune cells (ICs) between assays and the associations of expression levels with densities of TILs\/TAMs were also analysed. 405.9A11 demonstrated best specificity in HRS cells and best sensitivity in ICs. Positive expression of PD-L1 was more frequent in ICs (85.2%) than in HRS cells (48.1%). Different subgroups of background ICs, including tumour-associated macrophages (TAMs), were assessed and scored for CD4, CD8, FOXP3, and CD163 expression. PD-L1 expression on ICs was the factor most associated with the density of TAMs. 405.9A11 provided the most convincing PD-L1 expression results. Pathologists should report PD-L1 expression in a combined manner, including both the status of HRS cells and the percentage of PD-L1-positive ICs.<\/jats:p>","DOI":"10.1007\/s12308-023-00530-1","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T02:06:58Z","timestamp":1675217218000},"page":"7-16","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["PD-L1 immunohistochemistry assay optimization to provide more comprehensive pathological information in classic Hodgkin lymphoma"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0417-5727","authenticated-orcid":false,"given":"Yunfei","family":"Shi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Mi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumei","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqin","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianghong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,1]]},"reference":[{"issue":"6","key":"530_CR1","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","volume":"18","author":"MR Green","year":"2012","unstructured":"Green MR, Rodig S, Juszczynski P, Ouyang J, Sinha P, O'Donnell E, Neuberg D, Shipp MA (2012) Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res 18(6):1611\u20131618","journal-title":"Clin Cancer Res"},{"key":"530_CR2","doi-asserted-by":"crossref","unstructured":"Lin AY, Schnitter JM, Gordon LI (2022) Immune checkpoint blockade for the treatment of Hodgkin lymphoma. Immunotargets Ther 11(2253-1556 (Print)):1-10.","DOI":"10.2147\/ITT.S284988"},{"issue":"5","key":"530_CR3","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/leu.2013.310","volume":"28","author":"D Atanackovic","year":"2014","unstructured":"Atanackovic D, Luetkens T, Kroger N (2014) Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. Leukemia 28(5):993\u20131000","journal-title":"Leukemia"},{"issue":"2","key":"530_CR4","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41375-019-0545-2","volume":"34","author":"Y Song","year":"2020","unstructured":"Song Y, Gao Q, Zhang H, Fan L, Zhou J, Zou D, Li W, Yang H, Liu T, Wang Q et al (2020) Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study. Leukemia 34(2):533\u2013542","journal-title":"Leukemia"},{"issue":"24","key":"530_CR5","doi-asserted-by":"publisher","first-page":"7363","DOI":"10.1158\/1078-0432.CCR-19-1680","volume":"25","author":"Y Song","year":"2019","unstructured":"Song Y, Wu J, Chen X, Lin T, Cao J, Liu Y, Zhao Y, Jin J, Huang H, Hu J et al (2019) A single-arm, multicenter, phase II study of camrelizumab in relapsed or refractory classical Hodgkin lymphoma. Clin Cancer Res 25(24):7363\u20137369","journal-title":"Clin Cancer Res"},{"issue":"5","key":"530_CR6","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1093\/intimm\/8.5.773","volume":"8","author":"H Nishimura","year":"1996","unstructured":"Nishimura H, Agata Y, Kawasaki A, Sato M, Imamura S, Minato N, Yagita H, Nakano T, Honjo T (1996) Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes. Int Immunol 8(5):773\u2013780","journal-title":"Int Immunol"},{"issue":"6","key":"530_CR7","doi-asserted-by":"publisher","first-page":"7507","DOI":"10.1007\/s13277-015-4622-5","volume":"37","author":"YW Koh","year":"2016","unstructured":"Koh YW, Jeon YK, Yoon DH, Suh C, Huh J (2016) Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma. Tumour Biol 37(6):7507\u20137514","journal-title":"Tumour Biol"},{"issue":"4","key":"530_CR8","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ et al (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372(4):311\u2013319","journal-title":"N Engl J Med"},{"issue":"5","key":"530_CR9","doi-asserted-by":"publisher","first-page":"e234","DOI":"10.1016\/S1470-2045(15)70103-8","volume":"16","author":"EA Hawkes","year":"2015","unstructured":"Hawkes EA, Grigg A, Chong G (2015) Programmed cell death-1 inhibition in lymphoma. Lancet Oncol 16(5):e234\u2013e245","journal-title":"Lancet Oncol"},{"issue":"4","key":"530_CR10","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s11899-020-00589-y","volume":"15","author":"W Xie","year":"2020","unstructured":"Xie W, Medeiros LJ, Li S, Yin CC, Khoury JD, Xu J (2020) PD-1\/PD-L1 pathway and its blockade in patients with classic Hodgkin lymphoma and non-Hodgkin large-cell lymphomas. Curr Hematol Malig Rep 15(4):372\u2013381","journal-title":"Curr Hematol Malig Rep"},{"issue":"4","key":"530_CR11","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s00277-017-3226-0","volume":"97","author":"R Dada","year":"2018","unstructured":"Dada R (2018) Program death inhibitors in classical Hodgkin's lymphoma: a comprehensive review. Ann Hematol 97(4):555\u2013561","journal-title":"Ann Hematol"},{"issue":"23","key":"530_CR12","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","volume":"34","author":"MG Roemer","year":"2016","unstructured":"Roemer MG, Advani RH, Ligon AH, Natkunam Y, Redd RA, Homer H, Connelly CF, Sun HH, Daadi SE, Freeman GJ et al (2016) PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol 34(23):2690\u20132697","journal-title":"J Clin Oncol"},{"issue":"26","key":"530_CR13","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455\u20132465","journal-title":"N Engl J Med"},{"issue":"1","key":"530_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/intimm\/dxu095","volume":"27","author":"GK Philips","year":"2015","unstructured":"Philips GK, Atkins M (2015) Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. Int Immunol 27(1):39\u201346","journal-title":"Int Immunol"},{"issue":"10","key":"530_CR15","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1200\/JCO.2017.77.3994","volume":"36","author":"MGM Roemer","year":"2018","unstructured":"Roemer MGM, Redd RA, Cader FZ, Pak CJ, Abdelrahman S, Ouyang J, Sasse S, Younes A, Fanale M, Santoro A et al (2018) Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma. J Clin Oncol 36(10):942\u2013950","journal-title":"J Clin Oncol"},{"issue":"3","key":"530_CR16","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/bjh.17362","volume":"193","author":"J Veldman","year":"2021","unstructured":"Veldman J, Alsada ZND, van den Berg A, Plattel WJ, Diepstra A, Visser L (2021) Soluble PD-L1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma. Br J Haematol 193(3):506\u2013514","journal-title":"Br J Haematol"},{"issue":"5","key":"530_CR17","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/ejh.13033","volume":"100","author":"Y Tanaka","year":"2018","unstructured":"Tanaka Y, Maeshima AM, Nomoto J, Makita S, Fukuhara S, Munakata W, Maruyama D, Tobinai K, Kobayashi Y (2018) Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma. Eur J Haematol 100(5):511\u2013517","journal-title":"Eur J Haematol"},{"issue":"1","key":"530_CR18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40364-022-00378-0","volume":"10","author":"K Sankar","year":"2022","unstructured":"Sankar K, Ye JC, Li Z, Zheng L, Song W, Hu-Lieskovan S (2022) The role of biomarkers in personalized immunotherapy. Biomark Res 10(1):32","journal-title":"Biomark Res"},{"key":"530_CR19","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3389\/fmed.2019.00174","volume":"6","author":"Y Kambayashi","year":"2019","unstructured":"Kambayashi Y, Fujimura T, Hidaka T, Aiba S (2019) Biomarkers for predicting efficacies of anti-PD1 antibodies. Front Med (Lausanne) 6:174","journal-title":"Front Med (Lausanne)"},{"issue":"9","key":"530_CR20","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s40265-016-0588-x","volume":"76","author":"L Festino","year":"2016","unstructured":"Festino L, Botti G, Lorigan P, Masucci GV, Hipp JD, Horak CE, Melero I, Ascierto PA (2016) Cancer treatment with anti-PD-1\/PD-L1 agents: is PD-L1 expression a biomarker for patient selection? Drugs 76(9):925\u2013945","journal-title":"Drugs"},{"issue":"1878-1705 (Elec","key":"530_CR21","doi-asserted-by":"publisher","first-page":"105999","DOI":"10.1016\/j.intimp.2019.105999","volume":"77","author":"M Xie","year":"2019","unstructured":"Xie M, Huang X, Ye X, Qian W (2019) Prognostic and clinicopathological significance of PD-1\/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma. Int Immunopharmacol 77(1878-1705 (Electronic)):105999","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"530_CR22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","volume":"131","author":"ZY Xu-Monette","year":"2018","unstructured":"Xu-Monette ZY, Zhou J, Young KH (2018) PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood 131(1):68\u201383","journal-title":"Blood"},{"issue":"10","key":"530_CR23","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1158\/1078-0432.CCR-13-2702","volume":"20","author":"KA Schalper","year":"2014","unstructured":"Schalper KA, Velcheti V, Carvajal D, Wimberly H, Brown J, Pusztai L, Rimm DL (2014) In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res 20(10):2773\u20132782","journal-title":"Clin Cancer Res"},{"issue":"1","key":"530_CR24","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/labinvest.2013.130","volume":"94","author":"V Velcheti","year":"2014","unstructured":"Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, Herbst RS, Gettinger SN, Chen L, Rimm DL (2014) Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 94(1):107\u2013116","journal-title":"Lab Invest"},{"key":"530_CR25","doi-asserted-by":"publisher","unstructured":"Yuan J, Zhang J, Zhu Y, Li N, Tian T, Li Y, Li Y, Li Z, Lai Y, Gao J et al: Programmed death-ligand-1 expression in advanced gastric cancer detected with RNA in situ hybridization and its clinical significance. LID - https:\/\/doi.org\/10.18632\/oncotarget.9381 Oncotarget 2016(1949-2553 (Electronic)).","DOI":"10.18632\/oncotarget.9381"},{"key":"530_CR26","doi-asserted-by":"crossref","unstructured":"Duncan DJ, Scott M, Scorer P, Barker C (2019) Assessment of PD-L1 mRNA and protein expression in non-small cell lung cancer, head and neck squamous cell carcinoma and urothelial carcinoma tissue specimens using RNAScope and immunohistochemistry. PLoS One 14(4)","DOI":"10.1371\/journal.pone.0215393"},{"issue":"7","key":"530_CR27","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1111\/his.14651","volume":"80","author":"M Darmon-Novello","year":"2022","unstructured":"Darmon-Novello M, Adam J, Lamant L, Battistella M, Ortonne N, Balme B, de la Fouchardiere A, Chaltiel L, Gerard E, Franchet C et al (2022) Harmonization of programmed death-ligand 1 immunohistochemistry and mRNA expression scoring in metastatic melanoma: a multicentre analysis. Histopathology 80(7):1091\u20131101","journal-title":"Histopathology"},{"issue":"2","key":"530_CR28","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ygyno.2016.03.008","volume":"141","author":"JR Webb","year":"2016","unstructured":"Webb JR, Milne K, Kroeger DR, Nelson BH (2016) PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. Gynecol Oncol 141(2):293\u2013302","journal-title":"Gynecol Oncol"},{"issue":"5","key":"530_CR29","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1136\/gutjnl-2015-310839","volume":"66","author":"ED Thompson","year":"2017","unstructured":"Thompson ED, Zahurak M, Murphy A, Cornish T, Cuka N, Abdelfatah E, Yang S, Duncan M, Ahuja N, Taube JM et al (2017) Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut 66(5):794\u2013801","journal-title":"Gut"},{"issue":"3","key":"530_CR30","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.yexmp.2014.03.005","volume":"96","author":"JY Hou","year":"2014","unstructured":"Hou JY, Yu Z, Xiang RY, Li CQ, Wang L, Chen SF, Li QY, Chen M, Wang LY (2014) Correlation between infiltration of FOXP3(+) regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer. Exp Mol Pathol 96(3):284\u2013291","journal-title":"Exp Mol Pathol"},{"issue":"7","key":"530_CR31","doi-asserted-by":"publisher","first-page":"784","DOI":"10.7150\/jca.14549","volume":"7","author":"Z Li","year":"2016","unstructured":"Li Z, Dong P, Ren M, Song Y, Qian X, Yang Y, Li S, Zhang X, Liu F (2016) PD-L1 expression is associated with tumor FOXP3(+) regulatory t-cell infiltration of breast cancer and poor prognosis of patient. J Cancer 7(7):784\u2013793","journal-title":"J Cancer"},{"key":"530_CR32","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.lungcan.2019.08.023","volume":"136","author":"R Sumitomo","year":"2019","unstructured":"Sumitomo R, Hirai T, Fujita M, Murakami H, Otake Y, Huang CL (2019) PD-L1 expression on tumor-infiltrating immune cells is highly associated with M2 TAM and aggressive malignant potential in patients with resected non-small cell lung cancer. Lung Cancer 136:136\u2013144","journal-title":"Lung Cancer"},{"issue":"3","key":"530_CR33","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1309\/AJCP61TLMXLSLJYS","volume":"141","author":"JL Klein","year":"2014","unstructured":"Klein JL, Nguyen TT, Bien-Willner GA, Chen L, Foyil KV, Bartlett NL, Duncavage EJ, Hassan A, Frater JL, Kreisel F (2014) CD163 immunohistochemistry is superior to CD68 in predicting outcome in classical Hodgkin lymphoma. Am J Clin Pathol 141(3):381\u2013387","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"530_CR34","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3324\/haematol.2010.031542","volume":"96","author":"P Kamper","year":"2011","unstructured":"Kamper P, Bendix K, Hamilton-Dutoit S, Honore B, Nyengaard JR, d'Amore F (2011) Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma. Haematologica 96(2):269\u2013276","journal-title":"Haematologica"},{"issue":"6","key":"530_CR35","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1007\/s10147-017-1161-7","volume":"22","author":"X Zhang","year":"2017","unstructured":"Zhang X, Zeng Y, Qu Q, Zhu J, Liu Z, Ning W, Zeng H, Zhang N, Du W, Chen C et al (2017) PD-L1 induced by IFN-gamma from tumor-associated macrophages via the JAK\/STAT3 and PI3K\/AKT signaling pathways promoted progression of lung cancer. Int J Clin Oncol 22(6):1026\u20131033","journal-title":"Int J Clin Oncol"},{"issue":"9","key":"530_CR36","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1038\/s41375-020-0737-9","volume":"34","author":"M Kawashima","year":"2020","unstructured":"Kawashima M, Carreras J, Higuchi H, Kotaki R, Hoshina T, Okuyama K, Suzuki N, Kakizaki M, Miyatake Y, Ando K et al (2020) PD-L1\/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma. Leukemia 34(9):2405\u20132417","journal-title":"Leukemia"},{"issue":"3","key":"530_CR37","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s12185-018-2466-7","volume":"108","author":"Y Shi","year":"2018","unstructured":"Shi Y, Deng L, Song Y, Lin D, Lai Y, Zhou L, Yang L, Li X (2018) CD3+\/CD8+ T-cell density and tumoral PD-L1 predict survival irrespective of rituximab treatment in Chinese diffuse large B-cell lymphoma patients. Int J Hematol 108(3):254\u2013266","journal-title":"Int J Hematol"},{"issue":"2","key":"530_CR38","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/PAI.0000000000000594","volume":"27","author":"B Vennapusa","year":"2019","unstructured":"Vennapusa B, Baker B, Kowanetz M, Boone J, Menzl I, Bruey JM, Fine G, Mariathasan S, McCaffery I, Mocci S et al (2019) Development of a PD-L1 complementary diagnostic immunohistochemistry assay (SP142) for atezolizumab. Appl Immunohistochem Mol Morphol 27(2):92\u2013100","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"9","key":"530_CR39","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.jtho.2018.05.013","volume":"13","author":"MS Tsao","year":"2018","unstructured":"Tsao MS, Kerr KM, Kockx M, Beasley MB, Borczuk AC, Botling J, Bubendorf L, Chirieac L, Chen G, Chou TY et al (2018) PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project. J Thorac Oncol 13(9):1302\u20131311","journal-title":"J Thorac Oncol"},{"issue":"4","key":"530_CR40","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/annonc\/mdv009","volume":"26","author":"J Bellmunt","year":"2015","unstructured":"Bellmunt J, Mullane SA, Werner L, Fay AP, Callea M, Leow JJ, Taplin ME, Choueiri TK, Hodi FS, Freeman GJ et al (2015) Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol 26(4):812\u2013817","journal-title":"Ann Oncol"},{"issue":"6","key":"530_CR41","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1097\/PAI.0000000000000408","volume":"24","author":"C Roach","year":"2016","unstructured":"Roach C, Zhang N, Corigliano E, Jansson M, Toland G, Ponto G, Dolled-Filhart M, Emancipator K, Stanforth D, Kulangara K (2016) Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non-small-cell lung cancer. Appl Immunohistochem Mol Morphol 24(6):392\u2013397","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"4","key":"530_CR42","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/PAI.0000000000000857","volume":"29","author":"Y Li","year":"2021","unstructured":"Li Y, Vennapusa B, Chang CW, Tran D, Nakamura R, Sumiyoshi T, Hegde P, Molinero L (2021) Prevalence study of PD-L1 SP142 assay in metastatic triple-negative breast cancer. Appl Immunohistochem Mol Morphol 29(4):258\u2013264","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"13","key":"530_CR43","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","volume":"19","author":"BJ Chen","year":"2013","unstructured":"Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML, Yu H, Fletcher CD, Freeman GJ, Shipp MA et al (2013) PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 19(13):3462\u20133473","journal-title":"Clin Cancer Res"},{"issue":"1","key":"530_CR44","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1):23\u201334","journal-title":"N Engl J Med"},{"issue":"10","key":"530_CR45","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa0905680","volume":"362","author":"C Steidl","year":"2010","unstructured":"Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD et al (2010) Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 362(10):875\u2013885","journal-title":"N Engl J Med"},{"issue":"7","key":"530_CR46","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.3324\/haematol.2011.055459","volume":"97","author":"B Sanchez-Espiridion","year":"2012","unstructured":"Sanchez-Espiridion B, Martin-Moreno AM, Montalban C, Medeiros LJ, Vega F, Younes A, Piris MA, Garcia JF (2012) Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma. Haematologica 97(7):1080\u20131084","journal-title":"Haematologica"},{"issue":"12","key":"530_CR47","doi-asserted-by":"publisher","first-page":"e82870","DOI":"10.1371\/journal.pone.0082870","volume":"8","author":"JR Kim","year":"2013","unstructured":"Kim JR, Moon YJ, Kwon KS, Bae JS, Wagle S, Kim KM, Park HS, Lee H, Moon WS, Chung MJ et al (2013) Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS One 8(12):e82870","journal-title":"PLoS One"},{"issue":"18","key":"530_CR48","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1182\/bloodadvances.2017006346","volume":"1","author":"P Hollander","year":"2017","unstructured":"Hollander P, Kamper P, Smedby KE, Enblad G, Ludvigsen M, Mortensen J, Amini RM, Hamilton-Dutoit S, d'Amore F, Molin D et al (2017) High proportions of PD-1(+) and PD-L1(+) leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcome. Blood Adv 1(18):1427\u20131439","journal-title":"Blood Adv"},{"issue":"30","key":"530_CR49","doi-asserted-by":"publisher","first-page":"7604","DOI":"10.1200\/JCO.2005.02.6310","volume":"23","author":"THM Keegan","year":"2005","unstructured":"Keegan THM, Glaser SL, Clarke CA, Gulley ML, Craig FE, DiGiuseppe JA, Dorfman RF, Mann RB, Ambinder RF (2005) Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: a population-based study. J Clin Oncol 23(30):7604\u20137613","journal-title":"J Clin Oncol"},{"issue":"12","key":"530_CR50","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1158\/2326-6066.CIR-15-0116","volume":"3","author":"KM Mahoney","year":"2015","unstructured":"Mahoney KM, Sun H, Liao X, Hua P, Callea M, Greenfield EA, Hodi FS, Sharpe AH, Signoretti S, Rodig SJ et al (2015) PD-L1 antibodies to its cytoplasmic domain most clearly delineate cell membranes in immunohistochemical staining of tumor cells. Cancer Immunol Res 3(12):1308\u20131315","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"530_CR51","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1007\/s00277-015-2403-2","volume":"94","author":"S Paydas","year":"2015","unstructured":"Paydas S, Bagir E, Seydaoglu G, Ercolak V, Ergin M (2015) Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma. Ann Hematol 94(9):1545\u20131552","journal-title":"Ann Hematol"},{"issue":"16","key":"530_CR52","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1182\/blood-2013-06-508044","volume":"122","author":"P Greaves","year":"2013","unstructured":"Greaves P, Clear A, Owen A, Iqbal S, Lee A, Matthews J, Wilson A, Calaminici M, Gribben JG (2013) Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells. Blood 122(16):2856\u20132863","journal-title":"Blood"},{"issue":"6","key":"530_CR53","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1182\/blood-2007-05-085159","volume":"111","author":"R Yamamoto","year":"2008","unstructured":"Yamamoto R, Nishikori M, Kitawaki T, Sakai T, Hishizawa M, Tashima M, Kondo T, Ohmori K, Kurata M, Hayashi T et al (2008) PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 111(6):3220\u20133224","journal-title":"Blood"},{"issue":"5","key":"530_CR54","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1182\/blood-2003-07-2594","volume":"103","author":"NA Marshall","year":"2004","unstructured":"Marshall NA, Christie LE, Munro LR, Culligan DJ, Johnston PW, Barker RN, Vickers MA (2004) Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 103(5):1755\u20131762","journal-title":"Blood"},{"issue":"3","key":"530_CR55","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1189\/jlb.0906565","volume":"82","author":"T Tanijiri","year":"2007","unstructured":"Tanijiri T, Shimizu T, Uehira K, Yokoi T, Amuro H, Sugimoto H, Torii Y, Tajima K, Ito T, Amakawa R et al (2007) Hodgkin's reed-sternberg cell line (KM-H2) promotes a bidirectional differentiation of CD4+CD25+Foxp3+ T cells and CD4+ cytotoxic T lymphocytes from CD4+ naive T cells. J Leukoc Biol 82(3):576\u2013584","journal-title":"J Leukoc Biol"},{"issue":"7","key":"530_CR56","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.acthis.2014.06.003","volume":"116","author":"LW Zhao","year":"2014","unstructured":"Zhao LW, Li C, Zhang RL, Xue HG, Zhang FX, Zhang F, Gai XD (2014) B7-H1 and B7-H4 expression in colorectal carcinoma: correlation with tumor FOXP3(+) regulatory T-cell infiltration. Acta Histochem 116(7):1163\u20131168","journal-title":"Acta Histochem"},{"issue":"19","key":"530_CR57","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1182\/blood-2015-02-629600","volume":"126","author":"J Kiyasu","year":"2015","unstructured":"Kiyasu J, Miyoshi H, Hirata A, Arakawa F, Ichikawa A, Niino D, Sugita Y, Yufu Y, Choi I, Abe Y et al (2015) Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood 126(19):2193\u20132201","journal-title":"Blood"}],"container-title":["Journal of Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12308-023-00530-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12308-023-00530-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12308-023-00530-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T13:19:54Z","timestamp":1679577594000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12308-023-00530-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,1]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["530"],"URL":"https:\/\/doi.org\/10.1007\/s12308-023-00530-1","relation":{},"ISSN":["1868-9256","1865-5785"],"issn-type":[{"type":"print","value":"1868-9256"},{"type":"electronic","value":"1865-5785"}],"subject":[],"published":{"date-parts":[[2023,2,1]]},"assertion":[{"value":"18 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures above were approved by the Ethical Committee of our institution, and written consent was obtained from each individual in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approved the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}